In a pilot study, patients with metastatic melanoma receiving ipilimumab or pembrolizumab were subjected to SPECT/CT imaging with [99mTc]Tc-HYNIC-IL2 with the aim to detect tumor infiltrating lymphocytes (TILs) [85]. Here, IL2 is linked to neoplasm.